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The somatostatin receptor 2 (mSSTR2) is alternatively spliced into two isoforms (mSSTR2A and mSSTR2B) which differ at the C-terminus. Both 
receptors bind somatostatin peptides with a similar high affinity when stably expressed in CHO-Kl cells. However, the spliced form (mSSTR2B) 
mediates a more efficient inhibition of adenylate cyclase and is much more resistant o agonist-induced reduction of binding than the longer form 
(mSSTR2A). These findings indicate that alternative splicing may be a physiological mechanism to modulate receptor desensitization and G-protein 
coupling of mSSTR2. 
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1. INTRODUCTION 
Somatostatin (SS-14) and its N-terminally extended 
form SS-28 are widely distributed throughout the cen- 
tral nervous system and peripheral tissues. The peptides 
inhibit growth hormone release from the pituitary [l] 
and of insulin from the pancreas [2]. In the nervous 
system, they act as neurotransmitters or neuromodula- 
tors to inhibit neuronal firing [3], thus modulating com- 
plex behaviors, such as motor activity and cognition 
[4,5]. At the cellular level, the SS peptides act via recep- 
tors which are coupled to adenylate cyclase (AC) and 
ion channels by pertussis toxin sensitive G-proteins [6] 
resulting in inhibition of AC activity [7], reduction of 
calcium currents [8] and potentiation of potassium cur- 
rents [4]. Two pharmacologically distinct SS receptors 
have been postulated earlier [9,10], but recently, five 
distinct receptor subtypes (SSTRl to SSTRS) have been 
cloned [l l-191. In a previous study, we reported a fur- 
ther degree of diversification for the somatostatin recep- 
tor mSSTR2 which is alternatively spliced, generating 
two isoforms mSSTR2A and mSSTR2B. The two 
isoforms differ exclusively in the cytoplasmic C-termi- 
nus of the receptor, a region shown to be important for 
phosphorylation-dependent receptor desensitization 
[131* 
The unspliced isoform (mSSTR2A) has been shown 
to bind the natural agonists SS-14 and SS-28 as well as 
the synthetic agonists SMS 201-995 (octeotride) and 
MK-678 (seglitide) with high affinity [11,13,20]. How- 
ever, it is still unclear to which extent this isoform medi- 
*Corresponding author. Fax: (49) (89) 599-6216. 
ate the inhibition of AC. One group failed to observe 
any effect of mSSTR2A on AC after stable transfection 
into CHO-DG44 cells or transient transfection into 
COS-1 or HEK 293 cells [20,21] whereas others found 
an inhibition of AC after stable transfection into CHO- 
Kl cells [22]. 
In a preliminary study we observed that the 
mSSTR2B isoform mediates a strong inhibition of AC 
after stable transfection in CHO-Kl cells [23]. In the 
present study, we compare both the unspliced form 
mSSTR2A and the spliced isoform in their ability to 
mediate inhibiton of AC. In addition, since the C-termi- 
nus of G-protein coupled receptors has been shown to 
be important for phosphorylation-dependent receptor 
desensitization, we measured the loss of high affinity 
binding of both receptor isoforms after pretreatment 
with agonists. Finally, we constructed a C-terminally 
truncated mutant of mSSTR2A to further characterize 
the involvement of the C-terminus in the efficiency of 
AC inhibition and of receptor desensitization. 
2. MATERIALS AND METHODS 
2.1. Cloning ofexpression vectorsfor mSSTR2A, mSSTR.?B, 51 YAST 
To generate a clone expressing mSSTR2B, a 1.7 kb BamHVlFcoRV 
fragment of the clone 51CF3-1 [14] was subcloned into vector pcDNA 
I (Invitrogen, San Diego, USA). To clone the mSSTR2A receptor, 
PCR amplification of cDNA derived from DNAse-treated neuroblas- 
tomaxglioma cells (NGlOS-15) with sense primer SLP4 matching at 
nucleotides 554575 and antisense-primer SLP5 matching at nucleo- 
tides 1707-1686 of non-translated regions of mSSTR2B (51CF3-1) 
was performed [14]. The PCR product of 1493 base pairs (5lSCRI) 
was cleaved with X&I and the resulting 1.2 kb fragment was sub- 
cloned into pcDNA I to obtain the clone SlYA-1E expressing exclu- 
sively the unspliced isoform mSSTR2A. For the construction of the 
C-terminally truncated receptor 51YAST, the PCR product 51SCRI 
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was reamplified by PCR using the sense-primer SLW and the antis- 
ense-primer SLP61 (3’-TCATTCGTCCTGATTAGATCTG-5’). 
Primer SLPQ matches at nucleotides 34-55 of the intron of mSSTR2 
[14] and introduces a stop-codon (ochre) at amino acid position 347 
of mSSTR2A. A 1 .l kb XbaI fragment of 5 1YAST was subcloned into 
pcDNA I to obtain the expression clone 5lYASTE. Sequencing of the 
expression clones was performed by the chain termination method 
]241. 
2.2. Stable expression of mSSTR2 receptors in CHO-K1 cells 
2 pg of the expression plasmids (5lCF3-IE, SlYA-lE, 5lYASTE) 
were contransfected with 0.1 pg of the plasmid pcDNA I neo (Invitro- 
gen) into CHO-Kl cells (ATCC) using Lipofectin (BRL, Eggenstein, 
Germany). Stable transfectants were selected in NUT-F12 medium 
containing 600 pg/ml G418 (BRL) and 10% fetal calf serum (FCS). 
Clones expressing the highest levels of specific mRNA were selected 
and tested for binding of [‘251]Tyr”-SS-14 (see below). Two to three 
clones of each receptor showing similar high affinity binding were used 
for further analysis. 
2.3. Binding assays 
3 x lo5 stably transfected CHOW cells were seeded in 35 mm six- 
well dishes in NUT-F12 medium containing 10% FCS. One day later, 
the cells were washed with 10 mM HEPES buffer (pH 7.4) and incu- 
bated with buffer containing 10 mM HEPES @H 7.4), 5 mM MgCl,, 
0.5% (w/v) bovine serum albumin, 20 &ml bacitracin, 10,000 cpm 
[‘251]Tyr”-SS-14 (Amersham, Braunschweig, Germany) and the indi- 
cated concentrations of SS-14 , SS-28 (Saxon Biochemicals, Han- 
nover. Germany), SMS 201-995 (octreotide, Sandoz, Basle, Switzer- 
land) or MK 678 (MSD, Munich, Germany) for 60 min at 8°C. 
Thereafter the cells were washed three times with ice-cold 10 mM 
HEPES buffer (PH 7.4) and dissolved in 1 ml of 8 M urea/3 M acetic 
acid. The radioactivity in the dissolved cells was measured in a y- 
counter. Nonspecific binding was the binding of [‘251]Tyr”-SS-14 in 
the presence of 1 PM SS-14. The IC,, values for the SS peptides to 
displace [‘251]Tyr”-SS-14 from specific binding (= total binding minus 
nonspecific binding) were graphically determined by logit analysis. 
Agonist-induced loss of binding was tested as follows: stably trans- 
fected cells were washed twice with serum-free NUT-F12 medium 
(SFM) and pretreated with SFM containing 10 nM SMS 201-995 for 
1 h at 27’C or 0°C. The cells were then washed three times with 10 
mM HEPES buffer (PH 7.4) at room temperature followed by 60 min 
incubation with the binding buffer and [‘ZSIjTyr”-SS-14 as described 
above. 
2.4. CAMP assay 
Accumulation of CAMP was measured as follows: 1.5 x 10’ stably 
transfected CHO-Kl cells were seeded in 22 mm twelve-well dishes 
with NUT-F12 medium containing 10% FCS. The cells were then 
washed twice with SFM and pretreated with SFM containing 200kM 
isobutyhnethylxanthine for 30 min at 37°C. Thereafter, forskolin (25 
PM final concentration) or a combination of forskolin and somato- 
statin peptides were added in the indicated concentrations and the 
incubation continued for 30 min at 37°C. the reaction was terminated 
by removing the medium, scraping and sonicating the cells in 1 ml of 
ice-cold HCYEtOH (1 vol. of 1 N HCl/lOOvols. EtOH). After evopara- 
tion of the solution, the residue was dissoved in TE buffer and the 
CAMP content measured by a radioassay kit (Amersham, Braun- 
schweig, Germany). 
3. RESULTS 
The cloning and expression of the mSSTR2B receptor 
(346 amino acids) has been described [13]. 
For expressing the unspliced form of the mSSTR2 
receptor (mSSTR2A; 369 amino acids) cDNA derived 
from NG108-15 cells mRNA was amplified with the 
primers SLP4 and SPL5 directed against noncoding re- 
gions of mSSTR2 (Fig. 1; and section 2). The resulting 
PCR product of 1493 bases (51SCRI) contains the cod- 
ing region of mSSTR2A and the C-terminal sequences 
of mSSTR2B (Fig. 1). A 1.2 kb XbaI fragment of 
51 SCRI was subcloned into pcDNA I, generating the 
AUG 
mWTR2A 
mSSTR2 gnm 
51SCRI 
I II Ill IV v VI VII 5lYASl 
Fig. 1. Schematic representation of mSSTR2 gene, the mRNA coding for mSSTR2A and mSSTR2B, and the PCR amplification products 5lSCRI 
and 5lYAST. The C-terminus for mSSTR2A and mSSTR2B are depicted as shaded boxes. The primer SLW and SLP5 were used to PCR amplify 
5lSCRI. Primer SLP4 and SLP61 were used to PCR amplify the C-terminal truncated mutant receptor 5lYAST. X indicates XbaI restriction sites. 
261 
FEBSLETTERS October 1993 Volume 33 1, number 3 
@ potential N-linked glyccaytation site 
potentA phoepholytation site 
potential palmytoylation site 
Fig. 2. Membrane topology of the spliced isoform mSSTR2B, mSSTR2A and the C-terminal truncated mutant 51YAST. mSSTR2B differs from 
mSSTR2A in the C-terminal amino acid sequence after the potential palmitoylation site. 51YAST is a mutant receptor derived from truncation 
of mSSTR2A to 346 amino acids. 
expression clone 5 1 YA- 1 E encoding exclusively the 
unspliced isoform mSSTR2A (369 amino acids). 
The PCR product SlSCRI was reamplified using the 
primers SLP4 and SLP61. Primer SLP61 introduced a 
J&I restriction site and a stop mutation (ochre) at 
amino acid position 347 of mSSTR2A thus limiting the 
translation product to 346 amino acid (SlYAST; Fig. 
1). The 1.1 kb X&I fragment was subcloned in pcDNA 
I generating the expression clone 5 1YASTE. The amino 
acid sequences of the three receptors are depicted in Fig. 
2. 
In a first set of experiments the functional properties 
of the spliced isoform mSSTR2B were studied after sta- 
ble transfection into CHO-Kl cells. As seen in Fig. 3A, 
SS-14, SS-28, as well as the synthetic SS peptides SMS 
201-995 and MK-678 displaced [‘251]Tyr11-SS-14 from 
the newly expressed binding sites in CHO-Kl cells with 
a similar high affinity (I&s (nM): SS-14 0.58, SMS 
201-995 0.71, MK-678 0.83, SS-28 0.92). The binding 
affinities are within the same range as those reported for 
the unspliced isoform mSSTR2A from mouse and rat 
[11,12,20]. 
The ability of mSSTR2B to inhibit AC activity is 
depicted in Fig. 3B. Forskolin (25 PM) treatment re- 
sulted in an about 5-fold increase of CAMP levels as 
262 
compared to untreated cells. SS-14 and SS-28 mediated 
a dose-dependent inhibition of forskolin-stimulated 
CAMP accumulation by about 60% with an EC,, for 
SS- 14 of 5.1 nM and for SS-28 of 4.2 nM). Interestingly, 
the synthetic peptides SMS 201-995 and MK-678 were 
more effective inhibitors of the AC than the natural 
SS-peptides. They completely inhibit forskolin-induced 
CAMP accumulation with EQ of about 0.9 nM for 
MK-678 and 1 .l nM for SMS 201-995 (Fig. 3B). In wild 
type CHO-Kl cells lacking somatostatin receptors, 
none of the agonists inhibited forskolin-stimulated 
CAMP levels (data not shown). 
Co-incubation with 500 &ml pertussis toxin, a drug 
which uncouples receptors selectively from Gi-proteins 
and abolishes high affinity agonist binding to SSTR2 
receptors [20], antagonized the inhibition of AC activity 
by SS-28 (Fig. 4), demonstrating that a pertussis toxin- 
sensitive G-protein couples the mSSTR2B receptor to 
AC. 
In another series of experiments the pharmacological 
properties of mSSTR2B were compared with those of 
the unspliced isoform mSSTR2A and the C-terminally 
truncated receptor 5 1YAST after stable transfection 
into CHO-Kl cells (Fig. 5). In this experiment 
mSSTR2A, mSSTR2B and 51YAST bound SS-14 with 
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Fig. 3. Functional characterization of CHO-Kl cells expressing the spliced isoform mSSTR2B. (A) Binding of [“‘I]Tyr’‘-SS-14. The selected clone 
binds 1800 cpm in the absence and 300 cpm in the presence of 100 nM SS-14. (B) Dose dependence of inhibition of CAMP accumulation by different 
somatostatin agonists. CAMP levels were stimulated with 25 ,uM forskolin (FK) in the presence or absence of increasing amounts of SS peptides. 
All values are means of triplicate determinations and expressed in percent of maminum stimulation by forskolin. 
similar high affinity as measured by displacement of 
[‘251]Tyr11-SS-14 with SS-14 (I&s (nM): 0.51, 0.62, 
0.72, respectively), demonstrating that the C-terminus 
of the receptors has no major effect on high athnity 
agonist binding. 
As seen in Fig. 5B all three receptors mediated the 
inhibition of forskolin-stimulated AC by SS-14; how- 
ever, to a different degree. A dose of 100 nM SS-14 
inhibited forskolin-stimulated AC in cells expressing 
mSSTR2B by 61% and 51YAST by 55%, but was less 
effective in blocking forskolin-stimulated AC in cells 
expressing mSSTR2A (only about 33%). A similar ob- 
servation was obtained in two additional experiments 
with other independently transfected CHO-Kl cells. In- 
hibition of forskolin-stimulated AC by 100 nM SS-14 
(mean + S.E.M. of 3 experiments): mSSTR2B 57 + 9; 
mSSTR2A 31 + 10; 51YAST 53 + 12; P c 0.05 for 
mSSTR2B vs. mSSTR2A and mSSTR2B vs. 51YAST; 
Student’s t-test). These findings indicate that the length 
of the C-terminus can affect the coupling to AC. 
Somatostatin receptors have been shown to desensi- 
tize when chronically exposed to agonists [25]. Exposure 
of CHO-Kl cells expressing mSSTR2A and 51YAST to 
10 nM of SMS 201-995 for 1 h at 27°C caused a marked 
decrease of high affinity binding of [12SI]Tyr’1-SS-14 of 
70-80% compared to nonpretreated cells (Fig. SC). Pre- 
treatment of the cells with SMS 201-995 at 0°C did not 
result in a diminished binding (data not shown) indicat- 
ing that the SS peptide used for pretreatment had been 
removed effectively under the washing conditions. In 
contrast, a similar pretreatment of cells expressing the 
spliced isoform mSSTR2B caused only a 35% loss of 
[‘251]Tyr11-SS-14 binding. 
The time-course of agonist-dependent loss of 
[1251]Tyr11-SS-14 high affinity binding is illustrated in 
Fig. 6. CHO-Kl cells expressing mSSTR2A or 
mSSTR2B were pretreated with 10 nM SMS 201-995 
for 0 min, 5 min, 20 min or 60 min followed by removal 
of the agonist and subsequent determination of high 
affinity binding of [1251]Tyr11-SS-14. As compared to 
control (0 min), a 45% loss of high affinity [1251]Tyr11- 
SS-14 binding to mSSTR2A occurred within 5 min of 
receptor occupation by SMS 201-995. Within 20 min, 
loss of high affinity binding of [1251]Tyr11-SS-14 to 
mSSTR2A was almost maximal (about 80%). The re- 
mSSTR2B 
3 7 
CON FK FK+ FK+ 
ss ss+ 
PTX 
Fig. 4. Effect of pertussis toxin on inhibition of forskolin-stimulated 
CAMP accumulation in CHO-Kl cells expressing the spliced isoform 
mSSTR2B. Forskolin (FK, 25 PM)-stimulated CAMP accumulation 
was inhibited by 1 PM SS-28 (FK + SS). Co-incubation with pertussis 
toxin (PTX; 500 @ml) diminished this inhibition (FK + SS + PTX) 
by uncoupling the pertussis toxin-sensitive G-protein from the recep 
tor. CON = untreated cells. 
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Fig. 5. Comparison of the isoform mSSTR2B, mSSTR2A and the mutant receptor 51YAST stable expressed in CHO-Kl cells with regard to agonist 
binding, inhibition of adenylyl cyclase activity and agonist-dependent loss of binding. (A) Displacement of high-affinity binding of [‘251]Tyr”-SS-14 
to the receptors by increasing amounts of SS-14. (B) Inhibiton of forskolin-stimulated CAMP accumulation (FK) by 100 nM SS-14. (C) Agonist- 
dependent receptor desensitization: pretreatment of CHO-Kl cells stably expressing mSSTR2B, mSSTR2A or 51YAST with 10 nM SMS 201-995 
for 1 h at 27°C (PRE) caused a decrease of high-affinity [‘ZSI]Tyr”-SS-14 binding to the receptor, as compared to nonpretreated cells (CON). DIS 
shows the displacement of [‘25flTyr”-SS-14 binding to nonpretreated cells with 10 nM of SMS 201-995. All values are means of triplicate 
determinations and expressed in percent of control (CON) binding. 
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duction of [‘251]Tyr’1-SS-14 binding to mSSTR2B exhib- 
ited a similar time-course, but was much less pro- 
nounced. Only 30-35% of high affinity binding of 
[1251]Tyr’1-SS-14 were lost after 2&60 min pretreatment 
with SMS 201-995. 
4. DISCUSSION 
In the present study the pharmacological properties 
of the two isoforms of the somatostatin receptor sub- 
type 2 (mSSTR2A and mSSTR2B) after expression in 
CHO-Kl cells have been compared. Evidence was pro- 
vided that both isoforms exhibit a similar binding affin- 
ity to SS-14, but differ in their ability to inhibit AC and 
to loose binding upon treatment with agonist. 
The unspliced form mSSTR2A has previously been 
characterized after stable transfection into CHO-DG44 
or transient ransfection into CO&l and HEK 293 cells 
[l 1,20,21]. In these cells, however, mSSTR2A bound SS 
peptides with a high affinity, but failed to inhibit fors- 
kolin-stimulated CAMP accumulation [20]. In contrast, 
when stably transfected into CHO-Kl cells we consis- 
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Fig. 6. Time course of agonist-dependent loss of binding to the unspli- 
ted isorform mSSTR2A and the spliced isoform mSSTR2B. High 
affinity [‘251]Tyr”-SS-14 binding to CHO-KI cells expressing 
mSSTR2A and mSSTR2B was measured following pretreatment for 
0, 5, 20 or 60 min with 10 nM SMS 201-995. 
tently obtained an inhibition of forskolin-stimulated 
AC by SS peptides (Fig. 5). Similar results were recently 
obtained by Hadcock and coworkers after expression of 
rat mSSTR2A in CHO-Kl cells [22]. 
A possible explanation for these discrepant results is 
that different G-proteins are expressed in the cells used 
for transfection. Thus, the CHO-DG44 cell line expresses 
Gia3r but not Giorl, Gia2 or G,, [20]. In contrast, G,,,, 
Gla2, but not G,a3 and G,, were detected in CHO- Kl 
cells [26]. In addition, since Giorl has been shown to be 
necessary for coupling SRIF receptors to AC in AtT- 
20 cells [27], it is possible that the lack of Glorl in CHO- 
DG44 is one of the reasons for the failure of transfected 
mSSTR2A to mediate inhibition of AC in these cells. 
However, the absence of Gia, cannot be solely responsi- 
ble for the inability of mSSTR2A to inhibit AC activity 
in CHO-DG44 cells, since COS- 1 cells which express all 
subtypes of G,, subunits and HEK 293 cells which ex- 
press Gia, also failed to mediate SS inhibition of AC 
[20,21]. 
Both isoform mSSTR2A and mSSTR2B are nega- 
tively coupled to AC in transfected CHO-Kl cells; how- 
ever, the isoform mSSTR2B was more efficient, display- 
ing a higher inhibition of forskolin-stimulated CAMP 
accumulation. Moreover, C-terminal truncation of 
mSSTR2A to the same length as mSSTR2B (mutant 
receptor 51YAST) improved the ability of the receptor 
to inhibit AC activity compared to mSSTR2A (Fig. 5B), 
indicating that the efficiency of negative coupling to AC 
is dependent from the length of the C-terminus of 
mSSTR2. Although it has been shown that the third 
intracellular loop contains the primary regions respon- 
sible for specificity in receptor G-protein interactions 
[28], the C-terminus may act in concert to obtain full 
efficiency in receptor G-protein coupling. It is notewor- 
thy in this context that a variety of receptors which 
inhibit AC (D2, dopaminergic; cx2, adrenergic; A,, purin- 
ergic; M2, muscarinergic) possess a short C-terminus 
v91. 
An interesting finding was that in CHO-Kl cells ex- 
pressing mSSTR2B the effectiveness of the stable SS 
peptides SMS 201-995 and MK-678 in inhibiting AC 
was higher than that of the natural occurring peptides 
SS-14 and SS-28. Since the binding properties of the 
peptides were similar, it appears that the peptide differ 
in their ability to cause binding-induced conformational 
changes of mSSTR2B which, in turn, affects coupling 
to AC. 
Previous studies have shown that mSSTR2A trans- 
fected in CHO-DG44 cells exhibit a marked loss of 
agonist binding after pretreatment with SS-14 [20]. A 
similar observation was made in CHO-Kl cells express- 
ing mSSTR2A (Fig. 5C; Fig. 6) which showed a highly 
diminished agonist binding by about 80% after pretreat- 
ment with 10 nM SMS 201-995 for 60 min. The loss of 
binding was much less pronounced (about 30%) in 
CHO-Kl cells transfected with the spliced isoform 
mSSTR2B. On the other hand, cells expressing the C- 
terminally truncated receptor 51YAST showed a similar 
loss of agonist binding after pretreatment with SMS 
201-995 as those expressing mSSTR2A. This indicates 
that the molecular requirements for the agonist-induced 
decrease in binding reside within the C-terminal 15 
amino acids of 51YAST which are present in 
mSSTR2A, but not in mSSTR2B. 
Previous studies have shown that a prolonged treat- 
ment with SS analogs of AtT-20 pituitary cells which 
express mSSTR2A and mSSTR2B [ 13,301 desensitize 
the cells to inhibition of hormone release and CAMP 
formation [25]. This desensitization was associated with 
a reduced SS binding which most probably resulted 
from an uncoupling of the receptor from G-proteins 
[25]. Uncoupling of the /I2 receptor from G,-protein has 
been shown to involve phosphorylation by @ARK (/I, 
adrenergic receptor kinase) [31] at serine and threonine 
residues in the C-terminus of the receptor. Interestingly, 
evidence has been provided that /IARK is involved in 
the phosphorylation of SS receptors in S49 lymphoma 
cells which occurs upon desensitization to SS-14 [32]. 
We suggest, that phosphorylation of Ser333, Thr335, 
Ser”’ and Se? (Fig. 2) which are common for 
SIYAST and mSSTR2A but not mSSTR2B might be 
responsible for the profound desensitization of these 
receptors, since 51YAST behaves similar to mSSTR2A 
(Fig. SC) in agonist-dependent loss of binding. 
The presence of both isoforms in brain and pituitary 
tissues of various species ([ 13,301; Vanetti et al., in prep- 
aration) indicates that the alternative splicing may be a 
physiologiscal mechanism to modulate the coupling ef- 
ficiency or desenzitation of mSSTR2. 
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